Compare · Nootropic peptide
Cerebrolysin vs Semax
Both are nootropic peptide compounds. Here's how they line up on the evidence — graded the same way.
| Cerebrolysin | Semax | |
|---|---|---|
| Evidence | Preliminary human | Preliminary human |
| Class | Nootropic peptide | Nootropic peptide |
| Summary | Cerebrolysin has more human trial data than most research peptides, yet its largest rigorous stroke trial was neutral and independent reviews find little benefit. | A Russian-approved nootropic/neuroprotective peptide whose human evidence is real but small, mostly Russian-language, and methodologically thin. |
| Full profile → | Full profile → |
Cerebrolysin
Cerebrolysin is one of the more genuinely studied compounds in the "nootropic peptide" category. Unlike most research peptides, it has a real prescription history abroad, multiple randomized controlled trials, and several Cochrane systematic reviews. That sounds promising until you look at what…
Semax
Semax is a synthetic peptide developed in Russia in the late 1980s and used there as a prescription drug for stroke and cognitive disorders. It is not approved anywhere in the West, and most of the research is in Russian.